8 results about "Perfusion Culture" patented technology

Provided are methods for the creation of ultra-high density cryopreserved cell banks. In certain embodiments, these methods employ altered perfusion culture techniques that allow for production of ultra-high density cell cultures that can be cryopreserved at unexpectedly high cell densities without the need for any cell concentration steps, while retaining excellent cell viability and quality.

The utility model discloses an organoid automatic perfusion culture device, and the device comprises: upper cover structure, upper cover structure is equipped with liquid inlet and a plurality of shunt passageways for guiding perfusion liquid to a plurality of culture cavities below respectively, modular culture unit, modular culture unit includes a plurality of culture cavities, and the vertical fluid passage for liquid through is arranged below every culture cavity and extends along the vertical direction, modular culture unit has stackable configuration, and the four corners of every modular culture unit are provided with limit cooperation structure and are used for aligning and positioning with adjacent unit, the upper surface or lower surface of modular culture unit is equipped with annular sealing groove, and the O type sealing ring is embedded in sealing groove and is used for forming sealed contact under the stacked state, base structure, and the vertical fluid passage export of the lowermost layer modular culture unit is communicated with base structure, and the inside is provided with the confluence cavity and liquid outlet.

The present disclosure provides a bioengineered kidney construction method based on organoids and acellular scaffolds, which comprises first injecting pro-vascular stem cells into a kidney acellular scaffold material, and then culturing for several days through fluid circulation perfusion, and then injecting kidney organoids (KIO) into the scaffold material for perfusion culture after the kidney acellular scaffold material is recellularized. The bioengineered kidney obtained by the method of the present disclosure can be used as a graft for replacing kidney function. The present disclosure also provides a kidney organoid culture and expansion method, and the organoids obtained by the method contain not only kidney parenchymal cells such as glomerular cells and renal tubular cells, but also blood vessels and immune cells, which provides a good source of kidney parenchymal cells for the preparation of tissue-engineered kidneys.

This invention discloses a microfluidic chip and its fabrication method for constructing modular cell cultures, relating to the field of cell culture technology. The chip includes an upper plate and a lower plate. The upper plate includes a first flow channel and a second flow channel, while the lower plate includes multiple spaced-apart culture chambers, each with a different cross-sectional shape. This allows each chamber to be independently formed into cultures of different shapes. The cultures can be stacked and combined after removal to construct a multi-cell co-culture model with functional partitions, significantly improving structural complexity and biomimicry. The upper plate slides to switch the connection between the first and second flow channels and the culture chambers, enabling inoculation and culture modes. During inoculation, cultured cells are injected into the culture chamber through the first flow channel; during culture, the flow channel is switched to perfuse the culture chamber with culture medium, avoiding damage to the culture during residual gel removal. This simple operation improves the success rate and enhances the reliability of experimental results.

1. The name of the design product: cell interception device. 2. The use of the design product: for perfusion culture. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view.

The present application relates to the technical fields of cell bioengineering and regenerative medicine, and particularly relates to a mesenchymal stem cell aseptic engineering production device, which comprises a biological reaction tank, the sidewall of the biological reaction tank is provided with a liquid supplementing hole, the inner top wall of the biological reaction tank is fixedly connected with a fixing seat, the bottom of the fixing seat is provided with a driving assembly for outputting rotary power, the driving assembly comprises a gear ring, the bottom of the fixing seat is fixedly connected with a driving part, the output end of the driving part is coaxially fixedly connected with a first gear, the first gear is engaged with a plurality of second gears, the second gears are all engaged with the gear ring, and the second gears are all rotationally matched with fixing shafts, and the top ends of the fixing shafts are fixedly connected with the fixing seat. The present application drives the filter cage to rotate through the gear ring, drives the guide vanes to rotate through the rotating shaft, reduces the retention and accumulation of the cell carriers at the filter holes through the rotation of the filter cage, so that stable separation and drainage are realized in the long-period perfusion culture process, and the risk of filter unit blockage is reduced.

The present invention relates to methods for the production of Adeno-associated virus (AAV), comprising steps of providing a stable AAV producer cell line in which at least some or all genes encoding the components necessary for the production of AAV are stably integrated into the cell genome, and culturing said cells in perfusion culture during the AAV production step (i.e., during the N step), wherein said perfusion culture encompasses continuous replacement of spent media with fresh media, and wherein said continuous replacement of spent media with fresh media continues after the induction of AAV production.

This invention discloses a method for shortening the fermentation cycle and increasing the yield of recombinant human serum albumin (rHSA), belonging to the field of biofermentation technology. This invention aims to solve problems in existing technologies, such as low seed quality leading to a long fermentation lag period, decreased cell viability in the later stages of fermentation, and low protein expression efficiency and easy degradation due to product secretion stress. The core process includes: using N-1 perfusion culture technology in the seed amplification stage to prepare a high-density, high-activity, high-quality seed solution; and implementing an amino acid feeding strategy during the induction expression period in the production fermentation stage, specifically supplementing key nutrients (L-proline, L-leucine, and L-valine). Using the complete process of this invention, the fermentation expression level and product stability of rHSA can be significantly improved, the fermentation cycle can be greatly shortened, production intensity can be increased, and the overall production cost can be effectively reduced.